ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer
- Focus Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 01 Oct 2015 Planned initiation date changed from 1 Jul 2015 to 1 Oct 2015, according to ClinicalTrials.gov record.